Clinical Trials Logo
  1. Home
  2. Pseudomyxoma Peritonei
  3. NCT02834169
  4. Details
NCT02834169 Clinical Trial

French National Registry of Rare Peritoneal Surface Malignancies

Pseudomyxoma Peritonei Clinical Trial

— RENAPE  

Official title:
French National Registry of Rare Peritoneal Surface Malignancies (RENAPE Registry)

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT02834169
Other study ID # 69HCL16_0406
Secondary ID
Status Active, not recruiting
Phase N/A
First received June 30, 2016
Last updated August 18, 2017
Start date October 2010
Est. completion date December 2018

Study information
Verified date August 2017
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Despite advances in the management of and changes in clinical practice, little is known about the epidemiology, patterns of care and outcomes of rare peritoneal surface malignancies patients in France.

In order to better understand the characteristics of rare peritoneal surface malignancies and to evaluate treatment strategies, the RENAPE registry aims at the collection of data from patients presenting with a rare peritoneal surface malignancy in France. Data will be entered prospectively in a specifically designed and secured web database.

All RENAPE's centres and physicians are invited to register patients with a rare peritoneal surface malignancy diagnosis and to participate to the registry. Data will be evaluated within regular time frames, focusing on types of rare peritoneal surface malignancies, treatment modalities and patient outcomes (e.g. survival, recurrence), thereby contributing to the better understanding of these rare cancers.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 2171
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients are eligible if they have a histologically proven rare peritoneal surface malignancy.

Exclusion Criteria:

- Histological diagnostic of peritoneal surface malignancy not confirmed

- Expected clinical follow up data not available

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Non interventional
Data collection

Locations
Country Name City State
France Institut de Cancérologie de l'Ouest - Paul Papin Angers
France CHU Jean Minjoz Besancon
France Institut Bergonié Bordeaux
France Centre François Baclesse Caen
France Centre Jean Perrin Clermont-ferrand
France CHU Estaing Clermont-ferrand
France AP-HP Louis MOURIER Colombes
France CHU Bocage Dijon
France CHU A. Michallon La Tronche
France Centre Oscar Lambret Lille
France CHRU Claude Huriez Lille
France Centre Léon Bérard Lyon
France Hôpital La Timône Marseille
France Institut Paoli Calmettes Marseille
France Institut du Cancer Montpellier Montpellier
France CHU Nantes Hôtel-Dieu Nantes
France CHU L'Archet II Nice
France AP-HP La Pitié-Salpêtrière Paris
France AP-HP St Antoine Paris
France Institut Curie Paris
France AP-HP Lariboisière Paris Cedex 10
France AP-HP Hôpîtal Europeen Georges Pompidou Paris Cedex 15
France Hospices Civils de Lyon - Centre Hospitalier Lyon Sud - Service de Chirurgie Générale et Digestive - 165 chemin du grand Revoyet, Pierre-benite
France CHU Poitiers Poitiers
France Hôpital Robert Debré Reims
France CHU Charles Nicolle Rouen
France Institut Cancérologie de l'Ouest - René Gauducheau Saint Herblain
France CHU Nord St Etienne
France CHRU Hautepierre Strasbourg
France Hôpital Purpan Toulouse
France Institut Claudius Regaud Toulouse
France Institut de Cancérologie de Lorraine Vandoeuvre-les-nancy
France Institut Gustave Roussy Villejuif

Sponsors (1)
Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Incidence of rare peritoneal surface malignancies Collect detailed clinical and histological diagnosis for estimating annual incidence rate year 5
Secondary Impact of specific treatment strategies Collect detailed therapeutic strategies (surgical procedure, chemotherapy, etc.) on patients with rare peritoneal surface malignancies year 5
See also
  Status Clinical Trial Phase
Recruiting NCT04024917 - Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis N/A
Completed NCT02374411 - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients N/A
Recruiting NCT02073500 - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Active, not recruiting NCT01427101 - Results of CRS and Debulking in PMP Patients N/A
Active, not recruiting NCT04982146 - Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei Phase 1
Completed NCT04088786 - Phase I Trial HIPEC With Nal-irinotecan Phase 1
Not yet recruiting NCT06084780 - Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) Phase 2
Completed NCT01764789 - Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer N/A
Completed NCT02040142 - Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Phase 2
Withdrawn NCT04125225 - What Are the Experiences of Patients With Pseudomyxoma Peritonei?
Not yet recruiting NCT03976973 - BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei Phase 2
Recruiting NCT01617382 - Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
Completed NCT01652794 - Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Phase 1
Completed NCT01126346 - Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) N/A
Completed NCT05513183 - Severe Neutropenia After HIPEC Using Mitomycin-C
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Recruiting NCT03210298 - International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Active, not recruiting NCT02387203 - Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Phase 2
Terminated NCT04665921 - A Study of SGN-STNV in Advanced Solid Tumors Phase 1
Recruiting NCT05321329 - Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients Phase 2

External Links